Publication:

A Poly (Lactic Co Glycolic) Acid Based Dry Powder Inhaler for the Treatment of Pulmonary Tuberculosis

Thumbnail Image

Open/View Files

Primary BARTOLUCCI-DOCUMENT-2017.pdf (1.36 MB)
 Thesis_formatted_08-Nov-2017_mjb 01.pdf (1.28 MB)

Date

2017-11-13

Authors

Published Version

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Abstract

The goal of this paper was to investigate the feasibility of a novel Poly (Lactic Co Glycolic) Acid (PLGA) based Dry Powder Inhaler in the treatment of pulmonary tuberculosis. First line TB drugs are highly effective in treating TB, but the lengthy treatment course and side effects associated with their use impacts negatively on treatment compliance. The advantages of using a Dry Powder Inhaler containing a fixed dose combination of first line antitubercular drugs in a PLGA carrier are investigated. Issues relating to the adequacy of current World Health Organization dosing recommendations are discussed and a set of clinical trials is proposed to assess the safety and efficacy of the Dry Powder Inhaler.

Description

Other Available Sources

Research Data

Keywords

Biology, General

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

URI

http://nrs.harvard.edu/urn-3:HUL.InstRepos:37736755

Collections

DCE Theses and Dissertations

Endorsement

Review

Supplemented By

Related Stories